Pathogenic mechanisms and the prospect of gene therapy for choroideremia
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Choroideremia is a rare, X-linked disorder recognized by its specific ocular phenotype as a progressive degenerative retinopathy resulting in blindness. New therapeutic approaches, primarily based on genetic mechanisms, have emerged that aim to prevent the progressive vision loss. AREAS COVERED: This article will review the research that has progressed incrementally over the past two decades from mapping to gene discovery, uncovering the presumed mechanisms triggering the retinopathy to preclinical testing of potential therapies. EXPERT OPINION: While still in an evaluative phase, the introduction of gene replacement as a potential therapy has been greeted with great enthusiasm by patients, advocacy groups and the medical community.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 2×
“Indeed, a number of past, ongoing and planned clinical trials make use of AAV vector systems for gene delivery in diseases affecting the central nervous system as well as the eye [89-92].”
BackgroundEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“Indeed, a number of past, ongoing and planned clinical trials make use of AAV vector systems for gene delivery in diseases affecting the central nervous system as well as the eye [89-92].”
BackgroundLong-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273 · cited 1×
“The use of AAV-mediated gene transfer is being explored as a treatment for a number of human diseases, and results from clinical trials are showing that this therapeutic method is safe and effective in the long term -- up to 3 years -- in some conditions [82], including LCA [83].”
BackgroundHauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
MacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62117-0 · Cited by 796 · cited 2×
“No adverse events have been reported [78].”
Self-citationHolz, F. G., Bindewald-Wittich, A., Fleckenstein, M., Dreyhaupt, J., Scholl, H. P. N., & Schmitz-Valckenberg, S. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.11.041 · Cited by 619
Retinal degeneration in choroideremia: deficiency of rab geranylgeranyl transferase
Seabra, M. C., Brown, M. S., & Goldstein, J. L. (1993) · Science · doi:10.1126/science.8380507 · Cited by 337 · cited 1×
“Shortly thereafter, reports were published that demonstrated a functional relationship between the CHM gene product and Rab geranylgeranyl transferase (RabGGT) [17,18].”
BackgroundCloning of a gene that is rearranged in patients with choroideraemia
Cremers, F. P. M., van de Pol, D. J. R., van Kerkhoff, L. P. M., Wieringa, B., & Ropers, H.-H. (1990) · Nature · doi:10.1038/347674a0 · Cited by 333 · cited 1×
“reported that the CHM gene had been successfully cloned [16].”
BackgroundCereso, N., Pequignot, M. O., Robert, L., Becker, F., De Luca, V., Nabholz, N., Rigau, V., De Vos, J., Hamel, C. P., & Kalatzis, V. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.11 · Cited by 72
Silencing of the CHM Gene Alters Phagocytic and Secretory Pathways in the Retinal Pigment Epithelium
Gordiyenko, N. V., Fariss, R. N., Zhi, C., & MacDonald, I. M. (2010) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.09-4117 · Cited by 69 · cited 1×
“In support of that finding, depletion of REP1 in human RPE cells does not affect the internalization of photoreceptor outer segments but rather reduces their degradation within the RPE [70].”
BackgroundSelf-citation
Research works printed but not linked: 82
- MacDonald IM, GeneReviews® [Internet], 1993-2015
- van den Hurk JA, 1997, Hum Mutat, 9, 110, 10.1002/(SICI)1098-1004(1997)9:2<110::AID-HUMU2>3.0.CO;2-D · DOI · Paper page
- Jacobson SG, 2006, Invest Ophthalmol Vis Sci, 47, 4113, 10.1167/iovs.06-0424 · DOI · Paper page
- Morgan JI, 2014, Invest Ophthalmol Vis Sci, 55, 6381, 10.1167/iovs.13-13454 · DOI · Paper page
- Spaide RF, 2003, Ophthalmology, 110, 392, 10.1016/S0161-6420(02)01756-6 · DOI · Paper page
- Preising MN, 2009, Ophthalmology, 116, 1201, 10.1016/j.ophtha.2009.01.016 · DOI
- Kärnä J, 1986, Acta Ophthalmol Suppl, 176, 1
- Potter MJ, 2004, Ophthalmology, 111, 1905, 10.1016/j.ophtha.2004.04.028 · DOI
- Rudolph G, 2003, Ophthalmic Genet, 24, 203, 10.1076/opge.24.4.203.17232 · DOI
- Nussbaum RL, 1985, Am J Hum Genet, 37, 473
- Schwartz M, 1986, Hum Genet, 74, 449, 10.1007/BF00280505 · DOI
- Merry DE, 1989, Am J Hum Genet, 45, 530
- Sankila EM, 1989, Hum Genet, 84, 66, 10.1007/BF00210674 · doi:10.1007/bf00210674
- van de Pol TJ, 1990, Nucleic Acids Res, 18, 725, 10.1093/nar/18.4.725 · DOI
- Seabra MC, 1992, Cell, 70, 1049, 10.1016/0092-8674(92)90253-9 · DOI · Paper page
- Andres DA, 1993, Cell, 73, 1091, 10.1016/0092-8674(93)90639-8 · DOI · Paper page
- McTaggart KE, 2002, Hum Mutat, 20, 189, 10.1002/humu.10114 · doi:10.1002/humu.10114
- Sergeev YV, 2009, Mutat Res, 665, 44, 10.1016/j.mrfmmm.2009.02.015 · DOI · Paper page
- Esposito G, 2011, Hum Mutat, 32, 1460, 10.1002/humu.21591 · DOI
- Rosenberg T, 1986, Ophthalmic Paediatr Genet, 7, 205, 10.3109/13816818609004140 · doi:10.3109/13816818609004140
- Rosenberg T, 1987, Ophthalmic Paediatr Genet, 8, 139, 10.3109/13816818709031459 · doi:10.3109/13816818709031459
- Poloschek CM, 2008, Invest Ophthalmol Vis Sci, 49, 4096, 10.1167/iovs.08-2044 · DOI
- Rush ET, 2010, Semin Pediatr Neurol, 17, 51, 10.1016/j.spen.2010.02.008 · doi:10.1016/j.spen.2010.02.008
- Cremers FP, 1990, Am J Hum Genet, 47, 622
- Wang Q, 2011, Acta Otolaryngol, 131, 1117, 10.3109/00016489.2011.589405 · doi:10.3109/00016489.2011.589405
- Mukkamala K, 2010, Ophthalmic Genet, 31, 178, 10.3109/13816810.2010.497529 · doi:10.3109/13816810.2010.497529
- Lorda-Sanchez IJ, 2000, Ophthalmic Genet, 21, 185, 10.1076/1381-6810(200009)21:3;1-Z;FT185 · doi:10.1076/1381-6810(200009)21:3;1-z;ft185
- Lee TK, 2003, Can J Ophthalmol, 38, 364, 10.1016/S0008-4182(03)80047-9 · DOI
- Fujiki K, 1999, Graefes Arch Clin Exp Ophthalmol, 237, 735, 10.1007/s004170050305 · DOI
- MacDonald IM, 1998, Ophthalmology, 105, 1637, 10.1016/S0161-6420(98)99031-5 · DOI
- Pereira-Leal JB, 2000, J Mol Biol, 301, 1077, 10.1006/jmbi.2000.4010 · DOI · Paper page
- Barnard AR, 2014, Cold Spring Harb Perspect Med, 5, a017293, 10.1101/cshperspect.a017293 · DOI · Paper page
- Corbeel L, 2008, Eur J Pediatr, 167, 723, 10.1007/s00431-008-0740-z · DOI
- Seabra MC, 1995, J Biol Chem, 270, 24420, 10.1074/jbc.270.41.24420 · DOI · Paper page
- Larijani B, 2003, J Biol Chem, 278, 46798, 10.1074/jbc.M307799200 · DOI · Paper page
- Tolmachova T, 1999, Gene, 239, 109, 10.1016/S0378-1119(99)00371-6 · DOI
- Köhnke M, 2013, PLoS One, 8, e81758, 10.1371/journal.pone.0081758 · DOI
- Rak A, 2004, Cell, 117, 749, 10.1016/j.cell.2004.05.017 · DOI · Paper page
- Pylypenko O, 2003, Mol Cell, 11, 483, 10.1016/S1097-2765(03)00044-3 · DOI
- Strunnikova N, 2012, Adv Exp Med Biol, 723, 381, 10.1007/978-1-4614-0631-0_49 · DOI
- Sakamoto K, 2007, FASEB J, 21, 4087, 10.1096/fj.07-8713com · DOI · Paper page
- Zhou Q, 2013, Ophthalmic Physiol Opt, 33, 157, 10.1111/opo.12023 · DOI
- Wuthisiri W, 2013, Curr Opin Ophthalmol, 24, 389, 10.1097/ICU.0b013e3283641f91 · DOI
- Perez-Cano HJ, 2009, Am J Med Genet A, 149, 2134, 10.1002/ajmg.a.32727 · DOI
- Carrel L, 1999, Proc Natl Acad Sci USA, 96, 7364, 10.1073/pnas.96.13.7364 · DOI · Paper page
- Vajaranant TS, 2008, Ophthalmology, 115, 723, 10.1016/j.ophtha.2007.07.032 · doi:10.1016/j.ophtha.2007.07.032
- Hayasaka S, 1985, Retina, 5, 30, 10.1097/00006982-198500510-00007 · doi:10.1097/00006982-198500510-00007
- Heckenlively J, 1982, Am J Ophthalmol, 93, 733, 10.1016/0002-9394(82)90469-X · DOI
- Edwards TL, 2015, Eye (Lond), 29, 460, 10.1038/eye.2014.326 · DOI
- Robinson D, 1987, Retina, 7, 70, 10.1097/00006982-198700720-00002 · DOI
- Palejwala NV, 2014, Clin Ophthalmol, 8, 1675, 10.2147/OPTH.S68243 · doi:10.2147/opth.s68243
- Campos-Pavón J, 2014, Arch Soc Esp Oftalmol, pii: S0365-6691
- Endo K, 2000, Acta Ophthalmol Scand, 78, 483, 10.1034/j.1600-0420.2000.078004483.x · DOI
- Genead MA, 2011, Eye (Lond), 25, 84, 10.1038/eye.2010.157 · DOI
- Genead MA, 2012, Retina, 32, 826, 10.1097/IAE.0b013e3182215ae9 · doi:10.1097/iae.0b013e3182215ae9
- Salvatore S, 2013, Surv Ophthalmol, 58, 560, 10.1016/j.survophthal.2012.11.006 · DOI
- Grover AK, 2014, Mol Cell Biochem, 388, 173, 10.1007/s11010-013-1908-z · DOI
- Hoffman DR, 2014, JAMA Ophthalmol, 132, 866, 10.1001/jamaophthalmol.2014.1634 · DOI
- 10.1006/exer.2001.1126 · DOI
- Zhao DY, 2003, Arch Ophthalmol, 121, 967, 10.1001/archopht.121.7.967 · DOI
- Freund P, 2013, Invest Ophthalmol Vis Sci, 54, ARVO abstract 1
- Coussa RG, 2012, Ophthalmic Genet, 33, 66, 10.3109/13816810.2011.623261 · DOI
- Moosajee M, 2009, Invest Ophthalmol Vis Sci, 50, 3009, 10.1167/iovs.08-2755 · DOI
- Tolmachova T, 2006, J Clin Invest, 116, 386, 10.1172/JCI26617 · DOI · Paper page
- Tolmachova T, 2010, Invest Ophthalmol Vis Sci, 51, 4913, 10.1167/iovs.09-4892 · DOI · Paper page
- Krock BL, 2007, Proc Natl Acad Sci USA, 104, 4600, 10.1073/pnas.0605818104 · DOI · Paper page
- Syed N, 2001, Ophthalmology, 108, 711, 10.1016/S0161-6420(00)00643-6 · DOI
- MacDonald IM, 2005, Invest Ophthalmol Vis Sci, 46, ARVO abstract 5
- Syed R, 2013, Invest Ophthalmol Vis Sci, 54, 950, 10.1167/iovs.12-10707 · DOI · Paper page
- MacDonald IM, 2009, Surv Ophthalmol, 54, 401, 10.1016/j.survophthal.2009.02.008 · DOI
- Birch DG, 2013, JAMA Ophthalmol, 131, 1143, 10.1001/jamaophthalmol.2013.4160 · DOI · Paper page
- Kaiser PK, 2009, Trans Am Ophthalmol Soc, 107, 311
- Acton JH, 2013, Can J Ophthalmol, 48, 358, 10.1016/j.jcjo.2013.03.021 · DOI
- Moosajee M, 2008, Hum Mol Genet, 17, 3987, 10.1093/hmg/ddn302 · DOI
- Schwarz N, 2014, Hum Mol Genet, 24, 972, 10.1093/hmg/ddu509 · DOI
- 10.1089/hum.2010.067 · DOI
- Testa F, 2013, Ophthalmology, 120, 1283, 10.1016/j.ophtha.2012.11.048 · DOI · Paper page
- Anand V, 2003, Vision Res, 43, 919, 10.1016/S0042-6989(02)00389-9 · DOI
- Tolmachova T, 2013, J Mol Med (Berl), 91, 825, 10.1007/s00109-013-1006-4 · DOI · Paper page
- 10.1371/journal.pone.0061396 · DOI · Paper page
- Black A, 2014, J Gene Med, 16, 122, 10.1002/jgm.2768 · DOI · Paper page
- Bennett J, 1999, Proc Natl Acad Sci USA, 96, 9920, 10.1073/pnas.96.17.9920 · DOI · Paper page
Cited by
Choroideremia gene therapy phase 2 clinical trial: 24-month results
Lam, B. L., Davis, J. L., Gregori, N. Z., MacLaren, R. E., Girach, A., Verriotto, J. D., Rodriguez, B., Rosa, P. R., Zhang, X., & Feuer, W. J. (2019) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.09.012 · Cited by 161
Self-citationOcular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses
Ghoraba, H. H., Akhavanrezayat, A., Karaca, I., Yavari, N., Lajevardi, S., Hwang, J., Regenold, J., Matsumiya, W., Pham, B., Zaidi, M., et al. (2022) · Clinical Ophthalmology · doi:10.2147/opth.s364200 · Cited by 76
“There are some challenges for gene therapy in choroideremia, including insufficient resemblance of animal models to functional and morphological manifestations of the disease, and uncertainty of which retinal layer is affected most.(45,46) Gene therapy outcomes for choroideremia have been less successful than RPE65-re…”
BackgroundSubretinal timrepigene emparvovec in adult men with choroideremia: a randomized phase 3 trial
MacLaren, R. E., Fischer, M. D., Gow, J. A., Lam, B. L., Sankila, E.-M. K., Girach, A., Panda, S., Yoon, D., Zhao, G., & Pennesi, M. E. (2023) · Nature Medicine · doi:10.1038/s41591-023-02520-3 · Cited by 58
Self-citation
Metadata
- Authors
- Dimopoulos, I. S., Chan, S., MacLaren, R. E., & MacDonald, I. M.
- Venue
- Expert Opinion on Orphan Drugs
- Publisher
- Informa Healthcare
- Published
- 2015-05-10
- Volume
- 3
- Issue
- 7
- Pages
- 787-798
- ISSN
- 2167-8707 (ISSN-L)
- OpenAlex
- W1525227301
- Cited by
- 37
- References
- 10
- FWCI
- 1.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pathogenic mechanisms and the prospect of gene therapy for choroideremia. https://app.cochat.ai/papers/10.1517/21678707.2015.1046434
- The paper
- Dimopoulos, I. S., Chan, S., MacLaren, R. E., & MacDonald, I. M. (2015). Pathogenic mechanisms and the prospect of gene therapy for choroideremia. Expert Opinion on Orphan Drugs. https://doi.org/10.1517/21678707.2015.1046434
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.